Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions
Bleomycin (BLM) is a drug used to treat different types of neoplasms. BLM's most severe
adverse effect is lung toxicity, which induces remodeling of lung architecture and loss of …
adverse effect is lung toxicity, which induces remodeling of lung architecture and loss of …
Transforming growth factor-β: master regulator of the respiratory system in health and disease
Y Aschner, GP Downey - American journal of respiratory cell and …, 2016 - atsjournals.org
In this article, we review the biology and physiological importance of transforming growth
factor-β (TGF-β) to homeostasis in the respiratory system, its importance to innate and …
factor-β (TGF-β) to homeostasis in the respiratory system, its importance to innate and …
Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis
Idiopathic pulmonary fibrosis (IPF) is a form of progressive interstitial lung disease with
unknown etiology. Due to a lack of effective treatment, IPF is associated with a high mortality …
unknown etiology. Due to a lack of effective treatment, IPF is associated with a high mortality …
[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity
ZT Rosenkrans, CF Massey, K Bernau… - European journal of …, 2022 - Springer
Purpose The lack of effective molecular biomarkers to monitor idiopathic pulmonary fibrosis
(IPF) activity or treatment response remains an unmet clinical need. Herein, we determined …
(IPF) activity or treatment response remains an unmet clinical need. Herein, we determined …
Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis
Introduction Idiopathic pulmonary fibrosis is a progressive diffuse parenchymal lung disorder
of unknown etiology. Mesenchymal stem cell (MSC)-based therapy is a novel approach with …
of unknown etiology. Mesenchymal stem cell (MSC)-based therapy is a novel approach with …
Emerging inhalation aerosol devices and strategies: where are we headed?
Novel inhaled therapeutics including antibiotics, vaccines and anti-hypertensives, have led
to innovations in designing suitable delivery systems. These emerging design technologies …
to innovations in designing suitable delivery systems. These emerging design technologies …
Management of fibrosis: the mesenchymal stromal cells breakthrough
B Usunier, M Benderitter, R Tamarat… - Stem cells …, 2014 - Wiley Online Library
Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an
abnormal accumulation of extracellular matrix components. Despite its slow progression, it …
abnormal accumulation of extracellular matrix components. Despite its slow progression, it …
Emerging role of immune cells as drivers of pulmonary fibrosis
The pathogenesis of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and
other forms of interstitial lung disease, involves a complex interplay of various factors …
other forms of interstitial lung disease, involves a complex interplay of various factors …
Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review
Introduction Idiopathic pulmonary fibrosis (IPF), a fatal lung disease of unknown origin, is
characterized by chronic and progressive fibrosing interstitial pneumonia which …
characterized by chronic and progressive fibrosing interstitial pneumonia which …
[HTML][HTML] Role and new insights of pirfenidone in fibrotic diseases
DA Lopez-de la Mora, C Sanchez-Roque… - … journal of medical …, 2015 - ncbi.nlm.nih.gov
Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-
fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression …
fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression …